Amgen IncAMGN
What Amgen Inc does.
Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) discovers, develops, manufactures and delivers innovative medicines to fight some of the world’s toughest diseases. We focus on areas of high unmet medical need and leverage our expertise to strive for solutions that dramatically improve people’s lives, while also reducing the social and economic burden of disease. We helped launch the biotechnology industry more than 45 years ago and have grown to be one of the world’s leading independent biotechnology companies. Our robust pipeline includes potential first-in-class medicines at all stages of development. We have a presence in approximately 100 countries worldwide.
Amgen was incorporated in California in 1980 and became a Delaware corporation in 1987. Amgen operates in one operating segment: human therapeutics.
Following is a summary of significant developments affecting our business that have occurred and that we have reported since the filing of our Annual Report on Form 10-K for the year ended December 31, 2024.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $25.4B | $26.0B | $26.3B | $28.2B | $33.4B | $36.8B |
| Net income | $7.3B | $5.9B | $6.6B | $6.7B | $4.1B | $7.7B |
| Free cash flow | $9.9B | $8.4B | $8.8B | $7.4B | $10.4B | $8.1B |
More on AMGN.
- Amgen Inc summary
- Amgen Inc financial statements
- Amgen Inc key metrics
- Amgen Inc health scores and style box
- Amgen Inc earnings
- Amgen Inc dividends
- Amgen Inc valuation
- Amgen Inc ownership and insiders
- Amgen Inc peers
Figures from Amgen Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.